Clinical evidence shows that AposHealth (an FDA-cleared medical device) improves pain, stiffness, and function in people with knee osteoarthritis.
However, it’s uncertain if these improvements are clinically meaningful. The analyses suggest that AposHealth is cost saving by £1,958 per person when compared with standard care if knee surgery is delayed for 5 years. Because the evidence for the potential cost savings is limited, further data collection is recommended to understand if cost savings are made once AposHealth is used in the NHS.
Recent Posts
UC Biomed Building Investment: Advancing Research at the University of Coimbra
The Universidade de Coimbra (UC) is preparing to inaugurate its new UC Biomed building in the coming months, marking a significant milestone for the institution's biomedical research and teaching capabilities. According to recent updates, the facility—located at Polo III—has entered its final pha...
Overview of the Health Innovation Award 2026: Promoting Sustainable Solutions in Healthcare
The Health Innovation Award continues its mission in 2026 by spotlighting data-driven projects that advance sustainability across Portugal’s health sector. Launched by Faculdade de Medicina da Universidade de Lisboa, Sanofi, and NTT DATA Portugal, it invites submissions through its dedicated plat...
Commitment to Health Strategies in Portugal: A Pathway Towards Sustainable Change
In advancing health strategies in Portugal, the Ordem dos Farmacêuticos met with Adalberto Campos Fernandes to urge the country to move from promising ideas to concrete implementation of the